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Myelin is amembrane characterized by high lipid con-
tent to facilitate impulse propagation. Changes in
myelin fatty acid (FA) composition have been associ-
ated with peripheral neuropathy, but the specific role
of peripheral nerve FA synthesis in myelin formation
and function is poorly understood. We have found
that mice lacking sterol regulatory element-binding
factor-1c (Srebf1c) have blunted peripheral nerve FA
synthesis that results in development of peripheral
neuropathy.Srebf1c-nullmicedevelopRemakbundle
alterations and hypermyelination of small-caliber fi-
bers that impair nerve function. Peripheral nerves
lacking Srebf1c show decreased FA synthesis and
glycolytic flux, but increased FA catabolism and
mitochondrial function. These metabolic alterations
are the result of local accumulation of two endoge-
nous peroxisome proliferator-activated receptor-a
(Ppara) ligands, 1-palmitoyl-2-oleyl-sn-glycerol-3-
phosphatidylcholine and 1-stearoyl-2-oleyl-sn-glyc-
erol-3-phosphatidylcholine. Treatment with a Ppara
antagonist rescues the neuropathy of Srebf1c-null
mice. These findings reveal the importance of periph-
eral nerveFAsynthesis tosustainmyelin structureand
function.
INTRODUCTION
Peripheral neuropathies belong to a heterogeneous group of dis-
orders that negatively impact the function of one or more periph-
eral nerves. The incidence of peripheral neuropathies, which can
be either inherited or acquired, is 2.4% in the general population
and 8% in older adults (Hughes, 2002). One mechanism that hasCbeen proposed to explain the pathogenic basis of incapacitating
peripheral neuropathies is the inability of Schwann cells to prop-
erly assemble and/or maintain nervous system myelin (Roglio
et al., 2008; Saher et al., 2009; Verheijen et al., 2009; Viader
et al., 2013). Schwann cells constitute the glia of the peripheral
nervous system. In response to axonal signal neuregulin-1
(NRG1) type III (Taveggia et al., 2005) or, in the case of nerve
injury, NRG1 type I (Stassart et al., 2013), Schwann cells distin-
guish larger axons to build or regenerate myelin. Schwann cells
also associate with several unmyelinated small-diameter sen-
sory axons and surround them to form Remak bundles.
Myelin is a specialized membrane highly enriched in lipids that
provide the electrical insulation properties to allow efficient prop-
agation of neuronal action potentials. The most abundant lipids
in peripheral nervous system myelin are cholesterol and fatty
acids (FAs), the latter being conjugated to different families of
phospholipids and glycosphingolipids (Garbay et al., 2000). Dis-
orders in cholesterol metabolism (Correa-Cerro et al., 2006;
Fitzky et al., 2001; Pollock et al., 1983; Saher et al., 2009; Wassif
et al., 2001) and FA accumulation in peroxisomes (Kassmann
et al., 2007; Van Veldhoven, 2010; Wierzbicki et al., 2002) have
been associated with defects in myelin function. Moreover,
FAs have been shown to influence the biophysical properties
of myelin, and changes in the FA composition of myelin can alter
peripheral nerve myelin structure and function (Cermenati et al.,
2012; Verheijen et al., 2009).
Lipid synthesis is under the control of three different transcrip-
tion factors of the basic helix-loop-helix-leucine zipper family
referred to as sterol regulatory element-binding factors (Srebfs)
(Horton et al., 2002). Srebf2 is an activator of cholesterol biosyn-
thesis, while Srebf1a and Srebf1c, derived from a single gene via
alternate forms of exon 1, regulate cholesterol, FA, and triglycer-
ide synthesis (Liang et al., 2002). It is thought that Srebf1c, which
contains a shorter and weaker transcriptional activation domain
relative to Srebf1a, is an isoform that preferentially governs FA
and triglyceride synthesis (Liang et al., 2002). Loss of expression
of all three Srebf isoforms specifically in Schwann cells results inell Metabolism 21, 571–583, April 7, 2015 ª2015 Elsevier Inc. 571
hypomyelination and neuropathy, demonstrating the vital role of
lipid synthesis in peripheral nerve structure and function (Verhei-
jen et al., 2009). Interestingly, FAs required for myelin formation
can be either synthesized endogenously or slowly taken up
from the circulation or from other nerve compartments (Bourre
et al., 1987; Verheijen et al., 2003, 2009; Yao et al., 1980). This
latter observation raises the question of whether endogenous
FA synthesis is necessary to sustain myelin formation, maintain
nerve integrity, and thus protect against the development of pe-
ripheral neuropathy. Although the role of altered cholesterol
metabolism in peripheral neuropathy is well established (Saher
et al., 2011), the specific contribution of FA synthesis remains
poorly understood.
Here, we explored the extent to which lack of the key lipogenic
transcription factor Srebf1c could result in the development of
peripheral neuropathy. Using functional, morphological, and
morphometric analyses, we found that Srebf1c-null mice display
a neuropathic phenotype consisting in hypermyelinated small-
caliber fibers, the result of changes in myelin periodicity. Unex-
pectedly, transcriptomics andmetabolomics revealed activation
of peroxisome proliferator-activated receptor a (Ppara) signaling
in Schwann cells as a result of increased levels of two distinct
physiological Ppara ligands, 1-palmitoyl-2-oleyl-sn-glycerol-3-
phosphatidylcholine (PC-C16:0/C18:1) and 1-stearoyl-2-oleyl-
sn-glycerol-3-phosphatidylcholine (PC-C18:0/C18:1) (Chakra-
varthy et al., 2009; Liu et al., 2013). Ppara is a nuclear receptor
that directs uptake, utilization, and catabolism of FAs by
increasing expression of genes involved in FA transport, binding
and activation, and peroxisomal and mitochondrial FA b-oxida-
tion (Bantubungi et al., 2012; Kersten et al., 1999). As a con-
sequence of abnormal local Ppara activation, Srebf1c-null
Schwann cells exhibit increased FA utilization, a detrimental
condition that ultimately results in the development of peripheral
neuropathy.
RESULTS
Srebf1c-Null Mice Develop Peripheral Neuropathy
To explore the extent to which reduced FA synthesis affects
myelin structure and function and contributes to peripheral neu-
ropathy, we used mice lacking the major lipogenic transcription
factor Srebf1c (Liang et al., 2002). Full-body Srebf1c knockout
(KO) mice were studied at 2 and 10 months of age to evaluate
the development of peripheral neuropathy over time and in the
fed state to maximize expression of Srebf1c in wild-type mice
(Liang et al., 2002). Body weight and glycemia were unchanged
at either age (Figures S1A, S1B, S1M, and S1N), but circulating
total cholesterol and triglycerides were significantly decreased
in Srebf1c-null mice relative to wild-type littermates at both 2
and 10 months of age (Figures S1C, S1D, S1O, and S1P). RNA
and protein analyses showed that Srebf1c was virtually absent
in the sciatic nerve of KO mice (Figures S1S and S1T). These
studies also confirmed previous reports (de Preux et al., 2007)
indicating that Srebf1c is the main isoform expressed in periph-
eral nerves (Figure S1S).
To evaluate the presence of peripheral neuropathy in Srebf1c
KO mice, we used a battery of functional and morphological/
morphometric analyses. Thermal and mechanical nociceptive
threshold were both decreased at 2 and 10 months of age in572 Cell Metabolism 21, 571–583, April 7, 2015 ª2015 Elsevier Inc.Srebf1c-null mice (Figures S1E, S1F, 1A, and 1B), whereas nerve
conduction velocity (NCV) and intraepidermal nerve fiber (IENF)
density were reduced only at 10 months of age (Figures 1C,
1D, S1G, and S1H). Nerves from mice lacking Srebf1c did not
show fiber loss (Figures S1I and S1Q) or myelin infoldings (Fig-
ures S1J and S1R). Similar to some forms of human peripheral
neuropathy (Kennedy et al., 1996) and peripheral neuropathy in
other animal models (Viader et al., 2013), Srebf1c-null mice at
2 months of age showed subtle abnormalities of small unmyelin-
ated C fibers (Figure S1K) while myelin was unaltered (Fig-
ure S1L). Myelinating dorsal root ganglia (DRG)/Schwann cell
explant cultures from wild-type and Srebf1c KO mice indicated
that both genotypes myelinated in vitro to a similar extent
(Figures S2A and S2B). At 10 months of age, Srebf1c KO sciatic
nerves showed decreased g ratio of small-caliber fibers (1–4 mm
axon diameter), indicating a selective hypermyelination (Figures
1E and 1F). Large-caliber fibers exhibited no substantial
changes (Figure 1F). To better characterize the observed hyper-
myelination, we evaluated myelin periodicity, for hypermyelina-
tion can be due to increased membrane compaction or to
packing defects that lead tomyelin instability. Srebf1cKO sciatic
nerves showed expanded myelin periodicity relative to wild-type
nerves (Figure 1G). In addition, we detected decreased levels of
the structural protein Pmp22 (Figure S2C) along with a slight in-
crease in Remak bundle alterations (Figure 1H). Together, these
findings establish a requirement for Srebf1c activity to maintain
peripheral nerve structure and function.
Lack of Srebf1c Alters Metabolism and Decreases
Peripheral Nerve FA Synthesis
To probe the mechanism responsible for the nerve pathology
observed inSrebf1cKOmice, we performed transcriptome anal-
ysis on 10-month-old mice, the age at which defects in nerve
structure and function are most evident. Gene ontology analysis
revealed that the majority of differentially regulated genes be-
longed to metabolic processes, specifically lipid, carbohydrate,
and protein metabolism (Figure 2A). As expected, absence of
Srebf1c resulted in decreased expression of FA biosynthesis
genes (Figure 2B). In addition, we also found decreased expres-
sion of glycolytic genes. In contrast, expression of genes
involved in FA catabolism, the tricarboxylic acid (TCA) cycle,
mitochondrial function, and the unfolded protein response
(UPR) was unexpectedly increased (Figure 2B). Validation of a
series of genes involved in FA synthesis (Figure 2C) and quanti-
fication of total FAs (Figure 2D) confirmed the downregulation of
this pathway in sciatic nerve, while total cholesterol levels were
unaffected (Figure 2E). Notably, the amount of palmitic acid
(C16:0), the product of FA synthase (Fasn), was decreased in
Srebf1c KO sciatic nerve. Stearic acid (C18:0) and oleic acid
(C18:1), the substrate and product of stearoyl-CoA desaturase
1 (Scd1, a direct transcriptional target of Srebf1c) were respec-
tively increased (C18:0) and decreased (C18:1), in line with the
expression profile of Scd1 (Figure 2D). To establish the speci-
ficity of these lipid synthesis defects, total FAs were quantified
in liver. In spite of reduced expression of FA biosynthetic genes
(Figure S3B), the levels of hepatic C16:0, a hallmark of endoge-
nous FA synthesis, were unchanged (Figure S3A). In addition, the
relative abundance of other FAs analyzed showed a different
profile from that observed in sciatic nerve (Figure S3A). These
Figure 1. 10-Month-Old Srebf1c KO Mice Exhibit Peripheral Neuropathy
(A and B) Thermal and mechanical nociceptive threshold (n = 5 per group).
(C) NCV (n = 4 per group).
(D) IENF density (n = 5 per group).
(E) Representative images of small-caliber, hypermyelinated fibers in Srebf1c KO sciatic nerve. Arrows indicate hypermyelinated Srebf1c KO axons compared to
similar axons in wild-type sciatic nerve.
(F) g ratio of sciatic nerve myelinated fibers and quantification accounting for axon diameter. The square indicates small-caliber fibers (<4 mm).
(G) Ultra structural analysis of myelin periodicity shows that myelin sheaths are compacted but that the periodicity is enlarged in Srebf1c KO nerves. White bars
indicate ten major dense lines equal to nine periods.
(H) Quantification of altered axons per Remak bundle binned into groups and shown as a percentage of total axons. Representative figure of Remak bundles
in sciatic nerves. Asterisks indicate Remak bundle alterations. Inset shows lack of Schwann cell cytoplasm between altered axons indicated by black
arrows. Data are expressed as mean ± SEM and are representative of three experiments. p values determined by unpaired student’s t test. *p < 0.05, **p < 0.01,
and ***p < 0.001 versus wild-type.observations may be explained by the fed state of the mice and
by the primary exposure of the liver to nutritional cues leading to
increased uptake of FAs present in the diet. Consistent with this
notion, increased levels of the essential FA linoleic acid (C18:2)
were observed in the liver (Figure S3A) but not in the sciatic nerve
(Figure 2D) of Srebf1c KOmice. Collectively, these observations
corroborate the role of Srebf1c as a major lipogenic transcrip-
tion factor regulating FA synthesis in peripheral nerves whose
absence modifies metabolic gene expression.
Enhanced Oxidative Metabolism in Srebf1c KO Nerves
Because transcriptome analysis indicated that genes involved in
FA catabolism, the TCA cycle, and mitochondrial function were
upregulated in 10-month-old Srebf1c KO nerves (Figure 2B),
we evaluated the energy status of wild-type and Srebf1c KOCsciatic nerves. The levels of ATP, ADP, and AMP were all
increased in Srebf1c KO nerves (Figure 3A). More importantly,
the adenylate energy charge, an index of the energy status of
cells (Atkinson and Walton, 1967), was significantly reduced in
Srebf1c KO nerves (Figure 3A). The observed energy depletion
was confirmed by analysis of the phosphorylation status of the
energy sensor AMP-activated protein kinase (Ampk). Ampk is
activated by increases in the AMP/ATP ratio and phosphoryla-
tion at threonine 172, a marker of its activation (Hardie et al.,
2012). We detected increased Ampk phosphorylation relative
to total Ampk levels in the sciatic nerves ofSrebf1cKOmice (Fig-
ure 3B). In contrast, the liver in a fed state neither showed
different levels of ATP nor changes in Ampk phosphorylation sta-
tus, confirming that nerves lacking Srebf1c specifically experi-
enced energy depletion (Figures S3C and S3D). As a readoutell Metabolism 21, 571–583, April 7, 2015 ª2015 Elsevier Inc. 573
Figure 2. Gene Expression Impact of Srebf1c Deletion in 10-Month-Old Sciatic Nerve
(A) Gene ontology analysis of biological processes of differentially regulated genes in Srebf1c KO sciatic nerve.
(B) Heat map shows differentially expressed genes belonging to metabolic pathways most affected in Srebf1c KO sciatic nerve (n = 3).
(C) qRT-PCR analysis of Acaca, Fasn, Scd1, and Acly mRNA expression in sciatic nerves (n = 6 per group).
(D and E) Quantification of FAs and cholesterol in sciatic nerve (n = 5 per group). Data are expressed as mean ± SEM. p values determined by unpaired Student’s
t test. *p < 0.05, **p < 0.01, and ***p < 0.001 versus wild-type.of increased Ampk activity, we measured phosphorylation levels
of serine 79 of acetyl-CoA carboxylase alpha (Acaca), a classic
downstream target of this energy sensor (Hardie et al., 2012).
Acaca expression was decreased in Srebf1c KO nerves (Fig-
ure 2C), and total protein levels followed this trend; however,
Acaca serine 79 phosphorylation was greater in KO sciatic
nerves (Figure 3B). Inactivation of Acaca by phosphorylation is
linked to a shift in FA metabolism from synthesis toward oxida-
tion. Accordingly, expression of genes involved in FA b-oxidation
and FA uptake and transport were upregulated in Srebf1c KO
nerves (Figures 3C and S2D), indicating a boost in FA catabo-
lism. As further evidence of induced, active FA b-oxidation
(Koves et al., 2008), we found that the levels of short-chain acyl-
carnitines were increased in KO nerves (Figure 3D). The C2/C0
ratio (an index of b-oxidation of even number FAs) and the
C2+C3/C0 ratio (an index of b-oxidation of odd number FAs)
were both increased demonstrating a flux of FA b-oxidation to-
ward acetyl-CoA formation and entry into the TCA cycle (Fig-
ure 3E). These data are substantiated by an increase in the
NAD+/NADH ratio (Figure 3F) and by enhanced expression of
genes involved in the TCA cycle (Figure 3C). In contrast, the liver574 Cell Metabolism 21, 571–583, April 7, 2015 ª2015 Elsevier Inc.profile of acylcarnitines levels (Figure S4A) and FA catabolism
and TCA cycle gene expression were largely unchanged or
decreased (Figure S3B).
FA catabolism in peripheral nerve is dependent on mitochon-
drial function (Viader et al., 2013) and 10-month-old Srebf1c KO
nerves showed increased mitochondrial DNA content, a hall-
mark of mitochondrial biogenesis (Figure 4A). Furthermore, the
expression of transcription factors that regulate mitochondrial
function and that of structural subunits of the electron transport
chain (ETC) were increased at both the mRNA and protein levels
(Figures 4B and 4C). As evidence of increased mitochondrial
activity, we detected increased overall respiration coupled to
oxidative phosphorylation in Srebf1c KO sciatic nerves (Fig-
ure 4D). In addition, the activities of ETC complex I, II, and IV
were generally increased although only those of complex I and
IV reached statistical significance (Figure 4D). Increased mito-
chondrial activity is often coupled to the generation of reactive
oxygen species (ROS) (Hue and Taegtmeyer, 2009), and we
observed an increase in ROS production in Srebf1c KO nerves
(Figure 4E) that is likely buffered by a concurrent induction of
expression of superoxide dismutase 2 (Sod2) and catalase
Figure 3. Srebf1c KO Sciatic Nerve from 10-Month-Old Mice Displays Energy Depletion and Increased b-Oxidation
(A) Quantification of total ATP, ADP, and AMP levels analyzed by HPLC and adenylate energy charge in sciatic nerve (n = 6 per group).
(B) Western blot analysis and quantification of threonine 172 phosphorylated Ampk, total Ampk, serine 79 phosphorylated Acaca, and total Acaca in sciatic nerve
(n = 3 per group).
(C) Ppara, Acsl1, Acox1, Cpt1, Cpt2, Acadvl, Acadl, Acadm, Hadh, Acot2, Pdha1, Pdk4, Idh3a, Suclg1, andMdh2mRNA and Acadl protein expression in sciatic
nerve (n = 6 per group).
(D) Acylcarnitines levels in sciatic nerve (n = 4 per group).
(E) b-oxidation index of even (C2/C0 ratio) and odd (C2 + C3/C0 ratio) FAs in sciatic nerve (n = 4 per group).
(F) NAD+/NADH ratio in sciatic nerve (n = 3 per group). Data are expressed asmean ± SEM. p values determined by unpaired Student’s t test. *p < 0.05, **p < 0.01,
and ***p < 0.001 versus wild-type.(Cat) (Figure 4F). The GSH/GSSG ratio was unchanged between
wild-type and Srebf1c KO nerves (wild-type 0.56 ± 0.01; KO
0.55 ± 0.01; n = 6), excluding generalized oxidative stress in
peripheral nerves. Together, these findings demonstrate an in-
crease in FA catabolism and mitochondrial activity in peripheral
nerves that results from defects in FA synthesis arising from the
lack of Srebf1c.
Effects of Srebf1c Deficiency on Glucose and Protein
Metabolism
In peripheral nerves, a second metabolic pathway affected
by the lack of Srebf1c was glycolysis (Figures 2A and 2B). 10-
month-old Srebf1c KO nerves displayed decreased expression
of key genes in this pathway such as 6-phosphofructo-2-ki-
nase/fructose 2,6-bisphosphatase isoform 3 (Pfkfb3, also
known as Pfk2), an enzyme involved in the production of
activators of phosphofructokinase-1 (Pfk1) such as fructoseC2,6-bisphosphate (Figure 5A). Moreover, expression of phos-
phoglycerate kinase 1 (Pgk1) was also decreased while hexoki-
nase 1 (Hk1) and pyruvate kinase (Pk) levels were not affected
(Figure 5A). To extend these findings, we measured glucose
6-phosphate and fructose 6-phosphate (as a sum), fructose
1,6-bisphosphate, and pyruvate and lactate as the end prod-
ucts of glycolysis. The levels of glucose 6-phosphate/fructose
6-phosphate were unchanged in Srebf1c KO sciatic nerve, indi-
cating that glucose uptake is likely not affected (Figure 5B). On
the other hand, the levels of fructose 1,6-bisphosphate, pyru-
vate, and lactate were reduced in peripheral nerves of Srebf1c
KO mice (Figure 5B), suggesting that downregulation of Pfkfb3
expression may be the defective step in the glycolytic pathway
of Srebf1c KO sciatic nerve. Expression of pyruvate dehy-
drogenase kinase 4 (Pdk4), a negative regulator of the enzyme
that converts pyruvate from glycolysis into acetyl-CoA (pyruvate
dehydrogenase alpha 1, Pdha1), was increased in Srebf1c KOell Metabolism 21, 571–583, April 7, 2015 ª2015 Elsevier Inc. 575
Figure 4. Mitochondrial Function Is Increased in the Sciatic Nerve of 10-Month-Old Srebf1c KO Mice
(A) Mitochondrial DNA content of sciatic nerve (n = 5 per group).
(B) qRT-PCR analysis of Tfam, Tfb1m, Ppargc1a, mt-Nd1, Ndufb8, Sdhb, Etfdh, Uqcrc2, Cyt-c, mt-CoII, Cox7a1, and Atp5a1 (n = 6 per group).
(C) Western blot analysis of Tfam and indicated ETC subunits in sciatic nerve and relative quantification (n = 3 per group).
(D) Mitochondrial respiration and ETC complexes activity (n = 3 per group).
(E) Histochemical analysis of ROS production and relative quantification (n = 7 per group). Scale bar, 10 mm.
(F) Expression of Sod2 and CatmRNA (n = 6 per group). Data are expressed as mean ± SEM. p values determined by unpaired Student’s t test. *p < 0.05, **p <
0.01, and ***p < 0.001 versus wild-type; #p < 0.05 versus basal wild-type.nerves, which suggests reduced flux of pyruvate into the
TCA cycle (Figure 3C). The levels of pyruvate and lactate
were unchanged in Srebf1c KO liver (Figure S4D), but expres-
sion of glucokinase (Gck), a direct target of Srebf1c, was
decreased as has been previously reported (Liang et al., 2002)
(Figure S3B).
Peripheral neuropathies have been linked to perturbations in
endoplasmic reticulum (ER) homeostasis that engage the UPR
(D’Antonio et al., 2013; Viader et al., 2013). The gene expres-
sion profile of major players in the UPR and the phosphoryla-
tion status of eukaryotic translation initiation factor 2a (Eif2a),
a regulator of protein translation in the context of UPR, were
not significantly altered in Srebf1c KO peripheral nerves (Fig-
ures 5C and 5D). However, expression of genes associated
with ER quality control systems such as unfolded protein bind-
ing, ER protein folding, ER-associated degradation (ERAD),
and ubiquitination was significantly increased in Srebf1c KO576 Cell Metabolism 21, 571–583, April 7, 2015 ª2015 Elsevier Inc.nerves (Figure 5E). This protein-proofreading pathway controls
the native conformation of proteins such that properly folded
proteins are transported to their final destination while unfolded
or misfolded proteins are ubiquitinated and degraded (Ellgaard
and Helenius, 2003). The pattern of total protein ubiquitination
was significantly greater in Srebf1c KO peripheral nerves (Fig-
ure 5F), and the amino acid profile of Srebf1c KO sciatic nerve
showed a general increase in these metabolites consistent
with a higher rate of proteolysis (Figure S5A). These alterations
were specific to peripheral nerves, for liver and plasma from
Srebf1c KO mice did not display this pattern (Figures S5B
and S5C). Furthermore, expression of liver UPR (Figure S3B)
and ER quality control genes was not increased (data not
shown). These data suggest that reduced glucose oxidation
in Srebf1c KO peripheral nerves boosts expression of ER qual-
ity control genes and augments general protein ubiquitination
and degradation.
Figure 5. The Sciatic Nerve of 10-Month-Old Srebf1c KO Mice Shows Reduced Glycolysis and Induction of the ER Quality Control System
(A) qRT-PCR analysis of Hk1, Pfkfb3, Pgk1, and Pk expression (n = 6 per group).
(B) Levels of glucose 6-phosphate/fructose 6-phospate, fructose 1,6-bisphosphate, pyruvate, and lactate in sciatic nerve (n = 6 per group).
(C and D) (C) mRNA expression levels of Eif2a, Ern1, Xbp1, Ddit3, Atf4, and Bax (n = 6 per group), and (D) western blot analysis of serine 51 phosphorylated Eif2a
and total Eif2a and quantification (n = 3 per group).
(E and F) (E) Gene expression analysis of Canx, Dnajb9, Uggt1, Derl1, and Ube2g1 (n = 6 per group), and (F) western blot analysis of global protein ubiquitination
and its quantification (n = 3 per group). Data are expressed as mean ± SEM. p values determined by unpaired Student’s t test. *p < 0.05, **p < 0.01, and ***p <
0.001 versus wild-type.Activation of Ppara Specifically in Schwann Cells Drives
Development of Peripheral Neuropathy
To investigate the molecular basis of the metabolic changes
that characterize peripheral neuropathy development in Srebf1c
KO peripheral nerves, we next explored the extent to which
absence of Srebf1c results in aberrant Ppara signaling. Ppara
is a ligand-activated transcription factor that is a primary regu-
lator of FA catabolism (Bantubungi et al., 2012; Kersten et al.,
1999). Endogenous Ppara ligands include lipids in the phos-
phatidylcholine (PC) family, specifically PC-C16:0/C18:1 and
PC-C18:0/C18:1 (Chakravarthy et al., 2009; Liu et al., 2013). Us-
ing targeted metabolomics, 88 different glycerophospholipids
(GPLs) and 14 sphingolipids (SLs) were profiled in sciatic nerves
from 10-month-old Srebf1c KO and wild-type mice (Figure S5E).
Z score analysis of GPL and SL species statistically different be-
tween genotypes indicated that the most abundant species in
Srebf1c KO sciatic nerve were PC aa C34:1 and PC aa C36:1
(Figure 6A). Tandem mass spectrometry identified PC aa C34:1Cas PC-C16:0/C18:1 and PC aa C36:1 as PC-C18:0/C18:1 (Fig-
ures S6A and S6B). The levels of both of these species were
increased in Srebf1c KO peripheral nerves (Figure 6B). Analysis
of GPL and SL species in liver and plasma yielded a different
profile of changes in Srebf1c KO samples (Figures S4B and
S7A). Interestingly, the levels PC aa C34:1 and PC aa 36:1 in
Srebf1c KO livers were unchanged while those in plasma were
decreased (Figures S4C and S7B).
To investigate the functional consequences of these metabo-
lome changes, we first confirmed that the level of Ppara expres-
sion was not different between Srebf1c KO and wild-type nerves
(Figure 3C), and that Ppara-mediated transcription could be acti-
vated by PC-C16:0/C18:1 and PC-C18:0/C18:1 in a cell-based
assay (Figure S5D). We then used chromatin immunoprecipita-
tion (ChIP) assays in sciatic nerves to evaluate the level of Ppara
activity in situ. ChIP analysis of 10-month-old peripheral nerves
revealed greater enrichment of Ppara bound to its responsive
elements (PPRE) within the promoter of both acyl-CoA oxidaseell Metabolism 21, 571–583, April 7, 2015 ª2015 Elsevier Inc. 577
Figure 6. PC aa C16:0/C18:1 and PC aa C18:0/C18:1 Activate Ppara in Srebf1c KO Nerve
(A) Z score of significantly altered GPL and SL species levels in 10-month-old Srebf1c KO sciatic nerve relative to wild-type.
(B) PC aa C16:0/C18:1 and PC aa C18:0/C18:1 quantification (n = 4 per group).
(C) ChIP analysis of Ppara recruitment to Ppara responsive elements (PPRE), and of active Pol II within the Acox1 and Pdk4 promoters and 30 UTRs, respectively,
in sciatic nerves of 10-month-old mice (n = 6 per group).
(D) qRT-PCR analysis of Srebf1c, Fasn, Scd1, Pmp2, Fabp3, Cpt1a, Pdk4, Ppargc1a, Sdhb,mt-CoII, Pfkfb3, Pgk1, Canx, Dnajb9, Derl1, Uggt1, Ube2g1, Chka,
Chpt1, and Lpcat3 in sciatic nerve of 2-month-old mice (n = 5 per group).
(E) PC aa C16:0/C18:1 and PC aa C18:0/C18:1 levels in sciatic nerves at 2 months of age (n = 5 per group).
(F) Lactate levels in sciatic nerve of 2-month-oldmice (n = 5 per group). Data are expressed asmean ± SEM. p values determined by unpaired Student’s t test. *p <
0.05, **p < 0.01, and ***p < 0.001 versus wild-type.1 (Acox1) and Pdk4 genes (Figure 6C) in Srebf1c KO nerves.
We also detected increased amounts of polymerase II (Pol II)
at the 30 UTR of both Acox1 and Pdk4 genes in Srebf1c KO pe-
ripheral nerves, a strong indication that this greater level of Ppara
recruitment translates into an enhanced level of target gene
expression (Figure 6C). These ChIP data are supported by our
original RT-qPCR analysis that shows increased expression of
Acox1 and Pdk4 in Srebf1c KO peripheral nerves (Figure 3C).
To examine if our findings in Srebf1c KO peripheral nerves
could be ascribed primarily to either the glial or the neuronal
compartment, we used transcriptomics and metabolomics to
profile DRG from 10-month-old mice. Remarkably, despite
reduced expression of FA synthesis genes in Srebf1c KO DRG,
the level of expression of FA catabolism genes was not different
between genotypes (Figure S7C). More importantly, neither the
C2/C0 and C2+C3/C0 ratios nor the levels of PC-C16:0/C18:1
and PC-C18:0/C18:1 were altered in Srebf1c KO DRG (Figures
S7D and S7E). These findings indicate that absence of Srebf1c578 Cell Metabolism 21, 571–583, April 7, 2015 ª2015 Elsevier Inc.and the consequent reduction in FA synthesis primarily affects
Schwann cell physiology to bring about the observed glial
abnormalities.
Our observations in 10-month-old Srebf1c KO mice with well-
established peripheral neuropathy indicate that a metabolic shift
from glucose toward FA oxidation and altered ER quality control
are both present. Since either of these abnormalities could in
principle result in peripheral neuropathy, to discern which of
these aberrations may be the primary driver in disease develop-
ment we studied the peripheral nerves of 2-month-old wild-type
and Srebf1c KO mice. Because at this age Srebf1c KO mice
exhibit a significantly milder neuropathic phenotype, they are
likely to be more informative regarding the causal alteration
that drives defects in nerve structure and function in older ani-
mals. Gene expression analysis detected significant upregula-
tion of genes involved in FA uptake, transport, and catabolism,
as well as mitochondrial function in the sciatic nerve of 2-
month-old Srebf1c KO mice (Figure 6D), suggesting increased
Ppara activity. Consistent with this notion, the levels of the
endogenous Ppara ligands PC-C16:0/C18:1 and PC-C18:0/
C18:1 were increased in Srebf1c KO peripheral nerves at this
early age (Figure 6E). Importantly, the expression of choline
phosphotransferase 1 (Chpt1), an enzyme of the PC biosynthetic
pathway, was increased (Figure 6D). In contrast, the expression
of lysophosphatidylcholine acyltransferase 3 (Lpcat3) was re-
duced (Figure 6D). Lpcat3 is a remodeling enzyme that preferen-
tially uses polyunsaturated fatty acyl-CoAs as donors for lyso-
PC substrates (Lands, 1958). Because a decrease in Lpcat3
activity is expected to shift incorporation into lyso-PC from poly-
unsaturated to monounsaturated or saturated FAs, it is likely that
this defect results in the increased levels of PC-C16:0/C18:1 and
PC-C18:0/C18:1 measured in Srebf1c KO nerves. In contrast to
these metabolic differences indicative of induction of Ppara
signaling, we did not detect alterations in glycolysis or ER quality
control in 2-month-old Srebf1c KO nerves (Figures 6D and 6F),
suggesting that it is the induction of Ppara activity that drives
the development of peripheral neuropathy in these animals.
Interestingly, the changes in gene expression of key genes in
FA catabolism, glycolysis, and mitochondrial function seen
in vivo were recapitulated in the mouse Schwann cell line
MSC80 treated with either PC-C16:0/C18:1 or PC-C18:0/
C18:1 (Figure S7F).
Inhibition of Ppara Activity Ameliorates Peripheral
Neuropathy in Srebf1c KO Mice
To examine if inhibition of Ppara would reverse the neuropathic
phenotype, 10-month-old Srebf1c KO mice were treated either
with vehicle or the Ppara antagonist GW6471 (Xu et al., 2002)
for 15 days. Using ChIP assays we found that GW6471 treatment
induced in Srebf1c KO sciatic nerves recruitment of the tran-
scriptional corepressor NCoR to the PPRE of Acox1 and Pdk4,
indicating that the antagonist reached the sciatic nerve and
acted to block Ppara function (Figure 7D). As consequence of
GW6471 treatment, the functional (Figures 7A and 7B), morpho-
logical (Figure 7C), gene expression (Figure 7E), and acylcarni-
tine level (Figure 7F) abnormalities present in 10-month-old
Srebf1c KO nerves were reversed to those of peripheral neurop-
athy-free wild-type mice. These data indicate that inhibition of
anomalous Ppara activation can rescue the neuropathic pheno-
type seen in Srebf1c KO mice. Finally, to explore if the opposite
would also be true, wild-type mice were treated with either
vehicle or two different Ppara agonists (Wy14643 and fenofi-
brate) for 15 days. Treatment with these synthetic Ppara activa-
tors increased Ppara target gene expression and induced FA
oxidation in sciatic nerve (Figures 7I and 7J) and had a negative
impact on nerve functional parameters (thermal and mechanical
nociceptive thresholds Figures 7G and 7H), mimicking several
features of the neuropathic phenotype observed in Srebf1c KO
mice. Taken together, these results demonstrate that aberrant
activation of Ppara signaling in Srebf1c KO nerves induces a
metabolic shift toward FA oxidation that ultimately results in
the development of peripheral neuropathy.
DISCUSSION
Genetic models have demonstrated that alterations in choles-
terol (Saher et al., 2009) and lipid (Verheijen et al., 2009) meta-Cbolism, or peroxisomal FA catabolism (Kassmann et al., 2007;
Van Veldhoven, 2010; Wierzbicki et al., 2002) can result in pe-
ripheral myelin abnormalities and/or peripheral neuropathy, but
less is known about the impact of endogenous FA biosynthesis
on peripheral nerve integrity and function. The glial component
of the peripheral nervous system requires massive amounts of
FAs to properly myelinate peripheral nerves (Garbay et al.,
2000). Schwann cells fulfill this requirement by synthesizing
FAs and by taking up FAs from the bloodstream and from other
nerve structures (Bourre et al., 1987; Verheijen et al., 2003, 2009;
Yao et al., 1980). To directly evaluate the relevance of endoge-
nous FA synthesis on peripheral nerve structure and function,
here we studied a mouse model of blunted FA synthesis (Liang
et al., 2002), the Srebf1c KO. We have found that lack of the lipo-
genic transcription factor Srebf1c is sufficient to bring about pe-
ripheral neuropathy.
Peripheral neuropathy in Srebf1c KO mice is characterized by
altered functional, morphological, and morphometric parame-
ters. Due to altered myelin periodicity, 10-month-old Srebf1c
KO mice have hypermyelinated small-caliber fibers that appear
expanded and yield myelin instability, as shown by the decrease
in NCV measured in these mice. In addition, we also observed
subtle effects on Remak bundles, suggesting that reduced
FA synthesis affects both myelinating and non-myelinating
Schwann cells. Transcriptomic and metabolomic analyses in
10-month-old mice revealed that lack of Srebf1c induced a shift
from FA synthesis toward catabolism specifically in peripheral
nerves. These data are consistent with findings in KO models
of FA biosynthetic enzymes that show increased liver FA catab-
olism when fed either chow or high-carbohydrate or -fat diets
(Strable and Ntambi, 2010). However, in the fed state, Srebf1c
KO livers did not display increased oxidative metabolism, and
our observations in the sciatic nerve were restricted to this tis-
sue. Moreover, the increase in FA catabolism appears to be
Schwann cell specific, as we found no induction of this pathway
in DRG or in plasma.
The mechanism responsible for enhanced FA catabolism in
Srebf1c KO mice restricted to peripheral nerves appears to be
the accumulation of PC-C16:0/C18:1 and PC-C18:0/C18:1
specifically in the sciatic nerve. Increased levels of these two
endogenous Ppara ligands activate this transcription factor
in vivo primarily in Schwann cells, resulting in increased FA
catabolism and the eventual development of peripheral neurop-
athy (Figure 7K). This model is supported by the energy depletion
measured in Srebf1c KO nerves that resulted in Ampk activation
and the subsequent inhibition of Acaca, thus shifting FA flux
toward b-oxidation in Srebf1c KO nerves. Importantly, treatment
of 10-month-old Srebf1c KO mice with a Ppara antagonist
reversed the functional nerve deficits associated with peripheral
neuropathy, indicating that aberrant activation of Ppara-medi-
ated transcription is indeed the main driver of peripheral neurop-
athy in these mice.
Although they showed no defect in glucose uptake, 10-month-
old Srebf1c KO nerves also displayed deficiencies in glycolytic
gene expression. As a consequence, the levels of fructose
1,6-bisphosphate, pyruvate, and lactate were all decreased,
indicating that Srebf1c KO peripheral nerves had shifted from
glycolytic to oxidative metabolism. These results are noteworthy
considering that peripheral nerves rely on glucose and lactate toell Metabolism 21, 571–583, April 7, 2015 ª2015 Elsevier Inc. 579
Figure 7. Aberrant Ppara Signaling Drives Development of Peripheral Neuropathy in Srebf1c KO Mice
(A and B) Thermal and mechanical nociceptive threshold in 10-month-old mice treated either with vehicle or the Ppara antagonist GW6471 (n = 6 per group).
(C) g ratio of sciatic nerve small-caliber myelinated fibers (<4 mm) from mice in (A) and (B) (n = 3 per group).
(D) ChIP analysis of NCoR recruitment to Ppara responsive elements (PPREs) within the Acox1 and Pdk4 promoters from mice shown in (A) and (B) (n = 6 per
group).
(E) Expression of Acsl1, Acox1, Cpt1, Acadvl, Acadl, Acadm, Hadh, and Pdk4 mRNA in mice shown in (A) and (B) (n = 6 per group).
(F) b-oxidation index of even FAs in sciatic nerve of mice shown in (A) and (B) (n = 6 per group).
(G and H) Thermal and mechanical nociceptive threshold in wild-type mice (2 months old) treated with vehicle, Wy14643, or fenofibrate (n = 5 per group).
(I) Expression of Acsl1, Acox1, Cpt1, Acadvl, Acadl, Acadm, Hadh, and Pdk4 mRNA in sciatic nerve mice shown in (G) and (H) (n = 5 per group).
(J) Sciatic nerve b-oxidation index of even FAs in wild-type mice shown in (G) and (H) (n = 5 per group).
(K) Schematic representation of the putative molecular mechanism underlying neuropathy development in Srebf1c KO sciatic nerves. Data are expressed as
mean ± SEM. p values for three-group comparisons determined by one-way ANOVA followed by Tukey’s multiple comparison post hoc test. *p < 0.05, **p < 0.01,
and ***p < 0.001 versus wild-type or vehicle; #p < 0.05, ##p < 0.01, and ###p < 0.001 versus Srebf1c KO.maintain their function (Beirowski, 2013). Moreover, because en-
sheathing cells such as Schwann cells in the peripheral nervous
system provide metabolic support to fulfill the energy demand of
sustained axonal functions (Nave, 2010; Nave and Trapp, 2008),
the glycolytic deficiencies of Srebf1c KO Schwann cells could
negatively impact nerve function. Defects in glycolysis were
also accompanied by derangements in the ER quality control
system in Srebf1c KO sciatic nerves, as indicated by increased
protein ubiquitination and proteolysis.
Although we observed these abnormalities in glycolysis and
ER quality control in 10-month-old Srebf1c KO nerves, study
of younger mice with a milder neuropathy showed that the pri-
mary defect that drives development of peripheral neuropathy
in Srebf1c KO mice is a shift toward FA oxidation. Metabolome
and transcriptome profiles of peripheral nerves in these younger
mice revealed increased levels of PC-C16:0/C18:1 and PC-580 Cell Metabolism 21, 571–583, April 7, 2015 ª2015 Elsevier Inc.C18:0/C18:1 that are the result of induced PC synthesis as well
as altered PC remodeling and availability of local FAs, but no de-
fects in glycolysis or ER quality control.
Our findings suggest that Ppara activation plays a critical role
in the pathogenesis of peripheral neuropathy development, at
least in certain settings. Srebf1c KO mice displayed mechanical
and thermal hyperalgesia at both 2 and 10 months of age
along with increased levels of endogenous Ppara ligands and
augmented FA catabolism in peripheral nerves. Furthermore,
wild-type mice treated with synthetic Ppara agonists phenocop-
ied several aspects of the Srebf1c KO neuropathic phenotype. It
is tempting to suggest that these data provide a partial explana-
tion for the sporadic cases of peripheral neuropathy that have
been reported in humans treated with fibrates (Corcia et al.,
1999; Corrao et al., 2004; Gabriel and Pearce, 1976). However,
several studies have also demonstrated a beneficial effect of
Ppara agonists in a variety of animal pain models, including liga-
tion of the sciatic nerve to induce mechanical and thermal hyper-
algesia (Fehrenbacher et al., 2009; LoVerme et al., 2006). This
discrepancy is likely due to the anti-inflammatory effects of
Ppara activation in those models (LoVerme et al., 2006), effects
that are not seen in Srebf1c KO sciatic nerves.
In summary, our work reveals that lack ofSrebf1c results in de-
fects in FA synthesis and glycolysis that unexpectedly force
Schwann cells to rely on FAs as a fuel source and that FA catab-
olism in these cells is driven by the accumulation of endogenous
activators of Ppara, a critical regulator of FA catabolism. These
data provide new insight into the contribution of endogenous
FA synthesis to nerve homeostasis and function that when
impaired can lead to the development of peripheral neuropathy.
EXPERIMENTAL PROCEDURES
Animals
Srebf1c heterozygous null mice were purchased from The Jackson Laboratory
(B6;129S6-Srebf1tm1Jdh, stock number: 004365) and used to generate a col-
ony of homozygous Srebf1c KO animals. C57BL6/J were purchased from
Charles River. All experiments were conducted following the regulations of
the European Community (Directive 86/609/EEC, Official Journal L 358, 18/
12/1986 p. 0001-0028) and local regulations (e.g., Italian Legislative Decree
n. 116 - 27/01/1992) for the care and use of laboratory animals. The Italian Min-
istry of Health approved the animal protocols of this study (ministerial decree n.
295/2012-A).
Peripheral Neuropathy Assessment
All behavioral tests used to evaluate the degree of peripheral neuropathy were
performed in a blind fashion.
Thermal Nociceptive Threshold
Nociceptive threshold to radiant heat was quantified using the hot plate paw
withdrawal test. The test was carried out at both 50C ± 0.2C and 55C ±
0.2C.
Mechanical Nociceptive Threshold
The dynamic test was used to assess the development ofmechanical allodynia
in wild-type versus Srebf1c KO animals. The dynamic aesthesiometer test
(Ugo Basile) was calibrated to exert a progressively increasing punctate pres-
sure with a gram force ramp of 1 g/s. After a clear hind paw withdrawal, the
instrument automatically stopped the stimulus, and the gram force obtain indi-
cated the mechanical nociceptive threshold index.
NCV
Digital NCV and nerve action potential amplitudes were measured using an
electromyography apparatus (Myto2 ABN Neuro) to assess the sensory/motor
functional status, as previously described (Carozzi et al., 2013).
IENF Density
Peripheral nerve damage was assessed by the quantification of the IENF den-
sity in the skin of the hindpaw footpad collected at sacrifice (Lauria et al., 2005).
Morphometric Analysis and Transmission Electron Microscopy of
Myelin
Freshly isolated sciatic nerves fromwild-type and Srebf1cKOmice were cut in
segments (1 to 2mm length) and fixed. Samples were postfixed in 1%buffered
OsO4, dehydrated in an acetone gradient and embedded in TAAB low-viscos-
ity resin. Myelinated fibers were stained with toluidine blue. The number of fi-
bers per nerve, the g-ratio, the percentage of fibers with infoldings, the number
of altered axons in Remak bundles, and myelin periodicity were analyzed in ul-
trathin sections using a JEOL 1200 EXII electron microscope. The g ratio was
calculated as the quotient between the axon size and the fiber size.
Gene Expression and Microarray Analysis
RNA from sciatic nerve, DRG, and liver of wild-type and Srebf1c KOmice was
isolated with TRIzol (Invitrogen) and purified using the Nucleospin RNA II kit
(Macherey-Nagel). Samples were quantified by real-time PCR using SYBRCGreen or TaqMan probes on a CFX384 real time system using the iScriptTM
one-step qRT-PCR kit for SYBR Green or for probes (Bio-Rad Laboratories).
Target gene expression was normalized to 36B4. Primers and probes are avail-
able upon request. For microarray experiments, RNA was analyzed by the
Genopolis Consortium using an Affimetrix platform (GEO accession number
GSE65754). Gene Ontology biological process analysis was performed using
Panther software (http://www.pantherdb.org/).
Metabolomic Analyses
For metabolomic analyses, sciatic nerves, DRG, and liver were homogenized
in methanol with a tissue lyser. Aliquots of plasma and/or of methanolic ex-
tracts were directly processed according to the manufacturer’s instructions
(AbsoluteIDQ p180 Kit, Biocrates). Quantitative analysis of FAs was performed
as previously described (Cermenati et al., 2012).
Mitochondrial Respiration and ROS Production
All assays were performed with a DW1 Electrode Chamber (Hansatech Instru-
ments Ltd), and data were normalized to tissue weight. Respiration assays
were evaluated aspreviously reported (Rogers et al., 2011). ROSwere evaluated
on 10 mmcryostat sections of sciatic nerves as described byKerver et al. (1997).
Statistical Analysis
Statistical analyses were performed by Student’s t test for the comparison of
two different experimental groups, or one-way ANOVA with the indicated post
hoc test for multiple testing comparisons. All statistical analyses were per-
formed using GraphPad Prism (GraphPad Software).
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